Hepatitis A and B vaccine uptake and immunisation among men who have sex with men seeking PrEP: a substudy of the ANRS IPERGAY trial

Paul Le Turnier (1) , Isabelle Charreau (2) , Audrey Gabassi (3) , Diane Carette (4) , Laurent Cotte (5) , Gilles Pialoux (6) , Cécile Tremblay (7, 8, 9) , Bruno Spire (10, 11) , Marie-Laure Chaix (12) , Laurence Meyer (13) , Catherine Capitant (14) , Constance Delaugerre (15, 3) , François Raffi (16) , Jean-Michel Molina (17, 18)

1 Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]
2 INSERM - Institut National de la Santé et de la Recherche Médicale
3 Laboratoire de Virologie [CHU Saint-Louis]
4 UPD5 - Université Paris Descartes - Paris 5
5 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
6 CHU Tenon [AP-HP]
7 CR CHUM - Centre de Recherche du Centre Hospitalier de l’Université de Montréal
8 CHUM - Centre Hospitalier de l'Université de Montréal
9 CRSN/Faculté de médecine Université de Montréal
10 SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
11 ORS PACA - Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille]
12 Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales
13 CESP - Centre de recherche en épidémiologie et santé des populations
14 Service de maladies infectieuses et tropicales [Saint-Louis]
15 GenCellDis (U944 / UMR7212) - Génomes, biologie cellulaire et thérapeutiques
16 CIC Nantes - Centre d’Investigation Clinique de Nantes
17 AP-HP - Hopital Saint-Louis [AP-HP]
18 USPC - Université Sorbonne Paris Cité

Vaccination against hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended in men who have sex with men (MSM). We assessed HAV and HBV vaccine uptake in the nonimmune participants and their immunisation during follow-up of the ANRS IPERGAY (Intervention Préventive de l'Exposition aux Risques avec et pour les Gays) pre-exposure prophylaxis (PrEP) trial. During the ANRS IPERGAY trial among MSM (NCT 01473472), vaccination against HAV and HBV was offered free of charge to all nonimmune participants at baseline. We assessed anti-HAV IgGs and anti-hepatitis B surface (HBs) antibodies (Abs) at baseline, 1-3 months after each vaccine dose and on the last followup visit. Vaccination uptake and immunisation were analysed in non-immune participants with at least 6 months of follow-up after the 1st vaccine dose. A total of 427 MSM with a median age of 34.8 years were analysed. Median follow-up was 2.2 years (Q1-Q3, 1.6-2.9). Absence of anti-HAV IgG at baseline (50.4%, 215/427) was associated with younger age (p=0.0001). Among HAV non-immune participants, 96.1% (197/205) received one or more vaccine doses and 91.0% (172/189) received two vaccine doses. Among HBV non-immune participants, 97.6 % (81/83) received one or more vaccine doses and 78.4% (58/74) received three doses. On the last-visit sample, anti-HAV IgG and anti-HBs Abs were respectively detected in 94.8% (95% CI 90.0% to 97.7%) and 79.6% (95% CI 66.5% to 89.4%) of participants with complete vaccination and in 80.0% (95% CI 51.9% to 95.7%) and 40.0% (95% CI 16.3% to 67.7%) of participants with incomplete vaccination. Vaccine acceptability against HAV and HBV infections was very high in MSM starting PrEP. Immunisation was high in participants with a full vaccination scheme. Physicians must consider PrEP visits as major opportunities to propose and complete HAV and HBV vaccination in at-risk non-immune subjects.

Domaines: Sciences du Vivant [q-bio]

Paul Le Turnier, Isabelle Charreau, Audrey Gabassi, Diane Carette, Laurent Cotte, et al.. Hepatitis A and B vaccine uptake and immunisation among men who have sex with men seeking PrEP: a substudy of the ANRS IPERGAY trial. Sexually Transmitted Infections, 2022, pp.sextrans-2022-055634. ⟨10.1136/sextrans-2022-055634⟩. ⟨hal-03949047⟩